• HumexLib état grippal° powder for oral solution in sachets (paracetamol + pheniramine + vitamin C) Urgo (Rev Prescrire n° 368)
The manufacturer has chosen to print "Humex°" in bold on the box, in much larger characters than the nonproprietary names of the active ingredients, making it harder to see that it contains paracetamol. "Humex°" is displayed in this way on the boxes of the 20 or so products in this umbrella brand, each containing very different drugs.

• Surbronc toux sèche dextrométhorphane sans sucre° oral solution in sachets (dextromethorphan) Boehringer Ingelheim (Rev  Prescrire n° 374)
The INN is insufficiently visible on the box of this new umbrella brand, which also features an illustration of someone downing a drink in one, captioned "lemon punch flavour": a message that trivialises the dangers of an opioid that is sometimes misused as a recreational drug.

• AdvilMed° 100 mg and 400 mg tablets, 5% gel, oral suspension (ibuprofen) Pfizer Santé Familiale (Rev Prescrire n° 369) (a)
• Antarène Codéine° 200 mg/30 mg and 400 mg/60 mg tablets (ibuprofen + codeine) Élerté (Rev Prescrire n° 372)
• Cartrex° tablets (aceclofenac) Almirall (Rev Prescrire n° 374)
• FlectorEffigel° 1% cutaneous gel (diclofenac) Genévrier (Rev Prescrire n° 371)
• Ibufetum° 5% cutaneous gel (ibuprofen) Menarini (Rev Prescrire n° 366)
• NurofenCaps° 400 mg soft capsules (ibuprofen) Reckitt Benckiser Healthcare (Rev Prescrire n° 369)
• VoltarenActigo Intense° 2% cutaneous gel and VoltarenSpé° 1% cutaneous gel (diclofenac) Novartis Santé Familiale (Rev Prescrire n° 364 and n° 374)
These patient leaflets contain insufficient information about the harms of nonsteroidal anti-inflammatory drugs (NSAIDs) during pregnancy. They fail to warn patients about concerns that NSAIDs may provoke spontaneous abortion and malformations when taken during the first trimester of pregnancy, or about the sometimes irreversible renal damage reported in children following exposure to an NSAID during the second trimester. These leaflets only state that the product concerned is contraindicated from the sixth month of pregnancy. It would be better to avoid NSAIDs throughout pregnancy until this six-month cut-off has been shown to be relevant.

a- This product belongs to an umbrella brand.

• Biocadextro enfants sans sucre° syrup (dextromethorphan) Zambon
(Rev Prescrire n° 373)
• Clarix toux sèche codéthyline sans sucre° oral solution (ethylmorphine) Cooper (Rev Prescrire n° 365) (a)
• Fluimucil toux sèche dextrométhorphane adultes sans sucre° syrup (dextromethorphan) Zambon (Rev Prescrire n° 374) (a)
• Kaneuron° oral drop solution (phenobarbital) SERB (Rev Prescrire n° 372)
• Potassium Richard 3 pour cent° syrup (potassium) Richard (Rev Prescrire n° 369) (b)
• Primpéran° oral solution (metoclopramide) Sanofi Aventis (Rev Prescrire n° 373)
• Rivotril° oral drop solution (clonazepam) Roche (Rev Prescrire n° 373)
• Tanakan° oral solution (Ginkgo biloba) Ipsen Pharma (Rev Prescrire n° 365 and n° 368)
• Toplexil° syrup and Toplexil sans sucre° oral solution (oxomemazine) Sanofi Aventis (Rev Prescrire n° 365)
None of the bottles of these 10 products has a child-proof cap. They therefore expose children to the risk of massive ingestion and potentially serious adverse effects.

a- This product belongs to an umbrella brand.
b- No dosing device is supplied in the box. Users are therefore forced to measure doses using a household spoon, a cause of dosing errors.

• Azyter° eye drops (azithromycin) Théa (Rev Prescrire n° 369)
• Monoprost° eye drops (latanoprost) Théa (Rev Prescrire n° 366)
• Naabak° eye drops (N-acetylaspartyl-glutamic acid) Théa (Rev Prescrire n° 371)
• Tanakan° tablets (Ginkgo biloba) Ipsen Pharma (Rev Prescrire n° 365)
The primary packaging (single-dose containers or blister packs) of these four products fails to mention the nonproprietary name.

• Orofluco° capsule (fluconazole) Majorelle (Rev Prescrire n° 373)
The international nonproprietary name is not printed on the front of the box.

• Diffu K° capsules (potassium chloride) UCB Pharma (Rev Prescrire n° 369)
The strength is expressed differently on the various packaging articles, e.g. 313 mg of potassium on the box and 600 mg of microencapsulated potassium chloride on the blister packs, which could cause dosing errors.

• Selincro° (nalmefene) Lundbeck (Rev Prescrire n° 374)
The labelling of the blister packs is ambiguous: the packs are divided into pairs of tablets by perforations, and the international nonproprietary name and dose strength are printed just once across each pair of blister pockets. Patients could understand this to mean that the contents of two blister pockets correspond to one dose, leading them to ingest a double dose.

• Salbumol° 0.5 mg/1 ml solution for injection and Salbumol fort° 5 mg/5 ml solution for IV infusion (salbutamol) GlaxoSmithKline (Rev Prescrire n° 366) The graphics on the two boxes are similar and they could be confused, resulting in dosing errors.